1. Home
  2. AADI vs VRCA Comparison

AADI vs VRCA Comparison

Compare AADI & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AADI
  • VRCA
  • Stock Information
  • Founded
  • AADI 2011
  • VRCA 2013
  • Country
  • AADI United States
  • VRCA United States
  • Employees
  • AADI N/A
  • VRCA N/A
  • Industry
  • AADI Biotechnology: Pharmaceutical Preparations
  • VRCA Biotechnology: Pharmaceutical Preparations
  • Sector
  • AADI Health Care
  • VRCA Health Care
  • Exchange
  • AADI Nasdaq
  • VRCA Nasdaq
  • Market Cap
  • AADI 59.4M
  • VRCA 58.0M
  • IPO Year
  • AADI N/A
  • VRCA 2018
  • Fundamental
  • Price
  • AADI $2.98
  • VRCA $0.68
  • Analyst Decision
  • AADI Hold
  • VRCA Hold
  • Analyst Count
  • AADI 3
  • VRCA 5
  • Target Price
  • AADI $1.75
  • VRCA $6.00
  • AVG Volume (30 Days)
  • AADI 863.3K
  • VRCA 630.2K
  • Earning Date
  • AADI 03-12-2025
  • VRCA 02-27-2025
  • Dividend Yield
  • AADI N/A
  • VRCA N/A
  • EPS Growth
  • AADI N/A
  • VRCA N/A
  • EPS
  • AADI N/A
  • VRCA N/A
  • Revenue
  • AADI $25,070,000.00
  • VRCA $9,210,000.00
  • Revenue This Year
  • AADI $8.43
  • VRCA $64.32
  • Revenue Next Year
  • AADI $5.41
  • VRCA $83.90
  • P/E Ratio
  • AADI N/A
  • VRCA N/A
  • Revenue Growth
  • AADI 7.80
  • VRCA 187.45
  • 52 Week Low
  • AADI $1.21
  • VRCA $0.61
  • 52 Week High
  • AADI $3.81
  • VRCA $11.41
  • Technical
  • Relative Strength Index (RSI)
  • AADI 50.12
  • VRCA 41.77
  • Support Level
  • AADI $2.91
  • VRCA $0.62
  • Resistance Level
  • AADI $3.27
  • VRCA $0.76
  • Average True Range (ATR)
  • AADI 0.27
  • VRCA 0.06
  • MACD
  • AADI -0.06
  • VRCA 0.01
  • Stochastic Oscillator
  • AADI 11.68
  • VRCA 40.93

About AADI Aadi Bioscience Inc.

Aadi Bioscience Inc is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi's primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. It has one operating segment, which is the business of developing and commercializing proprietary therapeutic. Geographically, it is located in the United States.

About VRCA Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.

Share on Social Networks: